Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Jia, Lifeng ^a,b   Song, Qi ^b,c   Zhou, Chenyang ^a,b   Li, Xiaoming ^b   Pi, Lihong ^d   Ma, Xiuru ^e   Li, Hui ^b   Lu, Xiuying ^a   Shen, Yupeng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^c Medical College of PLA   (China)

^d HEBEI GENERAL HOSPITAL   (China)

^e HEBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; CISPLATIN; CYCLIN D1; DIHYDROARTEMISININ; GELATINASE A; GELATINASE B; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN BCL XL; PROTEIN MCL 1; STAT3 PROTEIN; VASCULOTROPIN; ARTEMISININ DERIVATIVE; JAK2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SPECIFICITY; G1 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; APOPTOSIS; ARTEMISININS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; JANUS KINASE 2; MALE; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958191350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147157     Document Type: Article

References (43)

1. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell. 1994; 77(1):63-71. Epub 1994/04/08. 0092-8674(94)90235-6 [pii]. PMID: 7512451.
2. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994; 264(5155):95-8. Epub 1994/04/01. PMID: 8140422.
3. Yokogami K, Yamashita S, Takeshima H. Hypoxia-induced decreases in SOCS3 increase STAT3 activation and upregulate VEGF gene expression. Brain Tumor Pathol. 2013; 30(3):135-43. doi: 10.1007/s10014-012-0122-0 PMID: 23104276.
4. Levy DE, Lee CK. What does Stat3 do? J Clin Invest. 2002; 109(9):1143-8. doi: 10.1172/JCI15650 PMID: 11994402; PubMed Central PMCID: PMC150972.
5. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 2002; 13(8):355-62. Epub 2002/08/24. PMID: 12193474.
6. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1):105-15. PMID: 10023775.
7. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13):2000-8. doi: 10.1038/sj.onc. 1205260 PMID: 11960372.
8. Adachi M, Cui C, Dodge CT, Bhayani MK, Lai SY. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral oncology. 2012; 48(12):1220-6. doi: 10.1016/j.oraloncology.2012.06.006 PMID: 22770899
9. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004; 4 (2):97-105. Epub 2004/02/18. doi: 10.1038/nrc1275 PMID: 14964307.
10. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004; 10(1):48-54. doi: 10.1038/nm976 PMID: 14702634.
11. Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012; 30(3):916-26. Epub 2011/02/23. doi: 10.1007/s10637-011-9645-1 PMID: 21340507.
12. Liu J, Zhang Q, Chen K, Kuang S, Chen W, Yu Q. Small-molecule STAT3 signaling pathway modulators from Polygonum cuspidatum. Planta Med. 2012; 78(14):1568-70. Epub 2012/08/03. doi: 10.1055/s-0032-1315121 PMID: 22855270.
13. Wu C, Liu J, Pan X, Xian W, Li B, Peng W, et al. Design, synthesis and evaluation of the antibacterial enhancement activities of amino dihydroartemisinin derivatives. Molecules. 2013; 18(6):6866-82. Epub 2013/06/12. doi: 10.3390/molecules18066866 molecules18066866 [pii]. PMID: 23752470.
14. Flobinus A, Taudon N, Desbordes M, Labrosse B, Simon F, Mazeron MC, et al. Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. J Antimicrob Chemother. 2014; 69 (1):34-40. Epub 2013/09/05. doi: 10.1093/jac/dkt346 dkt346 [pii]. PMID: 24003183.
15. Gao N, Budhraja A, Cheng S, Liu EH, Huang C, Chen J, et al. Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. Apoptosis. 2011; 16 (5):511-23. Epub 2011/02/22. doi: 10.1007/s10495-011-0580-6 PMID: 21336837.
16. Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 2001; 70(1):49-56. Epub 2002/01/05. PMID: 11764006.
17. Zhang CZ, Zhang H, Yun J, Chen GG, L PB. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol. 2012; 83(9):1278-89. doi: 10.1016/j. bcp.2012.02.002 PMID: 22342732
18. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin. 2007; 28(7):1045-56. Epub 2007/06/26. doi: 10.1111/j.1745-7254. 2007.00612.x PMID: 17588342.
19. Li T, Chen H, Wei N, Mei X, Zhang S, Liu DL, et al. Anti-inflammatory and immunomodulatory mechanisms of artemisinin on contact hypersensitivity. Int Immunopharmacol. 2012; 12(1):144-50. doi: 10. 1016/j.intimp.2011.11.004 PMID: 22122827.
20. Pi L, Li X, Song Q, Shen Y, Lu X, Di B. Knockdown of glucose-regulated protein 78 abrogates chemoresistance of hypopharyngeal carcinoma cells to cisplatin induced by unfolded protein in response to severe hypoxia. Oncol Lett. 2014; 7(3):685-92. doi: 10.3892/ol.2013.1753 PMID: 24527073; PubMed Central PMCID: PMC3919852.
21. Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer. 2008; 113(7 Suppl):1911-32. doi: 10.1002/cncr.23654 PMID: 18798532; PubMed Central PMCID: PMC2751600.
22. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther. 2006; 6(3):231-41. Epub 2006/03/01. doi: 10.1517/14712598.6.3.231 PMID: 16503733.
23. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002; 62 (12):3351-5. PMID: 12067972.
24. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006; 13(11):1235-42. Epub 2006/11/23. S1074-5521(06)00378-4 [pii] doi: 10.1016/j.chembiol.2006.09.018 PMID: 17114005.
25. Timofeeva OA, Tarasova NI, Zhang X, Chasovskikh S, Cheema AK, Wang H, et al. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A. 2013; 110(4):1267-72. Epub 2013/01/05. doi: 10.1073/pnas.1211805110 1211805110 [pii]. PMID: 23288901.
26. Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res. 2013. Epub 2013/01/17. 0008-5472.CAN-12-3175 [pii] doi: 10.1158/0008-5472.CAN-12-3175 PMID: 23322008.
27. Kandala PK, Srivastava SK. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3). BMC Med. 2012; 10:9. Epub 2012/01/28. doi: 10.1186/1741-7015-10-9 1741-7015-10-9 [pii]. PMID: 22280969; PubMed Central PMCID: PMC3298725.
28. Kamran MZ, Gude RP. Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed Pharmacother. 2013; 67(5):399-405. Epub 2013/05/04. doi: 10. 1016/j.biopha.2013.03.020 S0753-3322(13)00049-8 [pii]. PMID: 23639230.
29. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009; 16 (6):487-97. Epub 2009/12/08. doi: 10.1016/j.ccr.2009.10.015 S1535-6108(09)00384-5 [pii]. PMID: 19962667; PubMed Central PMCID: PMC2812011.
30. Huang C, Cao J, Huang KJ, Zhang F, Jiang T, Zhu L, et al. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci. 2006; 97(12):1417-23. Epub 2006/10/24. CAS340 [pii] doi: 10.1111/j.1349-7006.2006.00340.x PMID: 17054436.
31. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003; 63 (6):1270-9. PMID: 12649187.
32. Zhang X, Song Y, Wu Y, Dong Y, Lai L, Zhang J, et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer. 2011; 129(10):2502-11. Epub 2011/01/06. doi: 10.1002/ijc.25909 PMID: 21207415.
33. Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, et al. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol Cancer. 2013; 12 (1):114. doi: 10.1186/1476-4598-12-114 PMID: 24093956; PubMed Central PMCID: PMC3853770.
34. Wong AL, Soo RA, Tan DS, Lee SC, Lim JS, Marban PC, et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015; 26(5):998-1005. doi: 10.1093/annonc/mdv026 PMID: 25609248.
35. Lu JJ, Chen SM, Zhang XW, Ding J, Meng LH. The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest New Drugs. 2011; 29(6):1276-83. Epub 2010/07/08. doi: 10.1007/s10637-010-9481-8 PMID: 20607588.
36. Handrick R, Ontikatze T, Bauer KD, Freier F, Rubel A, Durig J, et al. Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther. 2010; 9(9):2497-510. Epub 2010/07/29. 1535-7163.MCT-10-0051 [pii] doi: 10.1158/1535-7163.MCT-10-0051 PMID: 20663933.
37. Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, et al. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol. 2010; 80(1):22-30. Epub 2010/03/09. S0006-2952(10)00158-9 [pii] doi: 10.1016/j.bcp. 2010.02.016 PMID: 20206143.
38. Nam S, Xie J, Perkins A, Ma Y, Yang F, Wu J, et al. Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol. 2012; 6(5):484-93. Epub 2012/06/22. doi: 10.1016/j.molonc.2012.05.002 S1574-7891(12)00054-3 [pii]. PMID: 22717603; PubMed Central PMCID: PMC3439602.
39. Li X, Wang H, Lu X, Di B. Silencing STAT3 with short hairpin RNA enhances radiosensitivity of human laryngeal squamous cell carcinoma xenografts in vivo. Exp Ther Med. 2010; 1(6):947-53. Epub 2010/11/01. doi: 10.3892/etm.2010.156 etm-01-06-0947 [pii]. PMID: 22993624; PubMed Central PMCID: PMC3446739.
40. Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, Zhang L, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep. 2010; 23(3):671-6. Epub 2010/02/04. PMID: 20127005.
41. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol. 2008; 73(6):1632-42. doi: 10.1124/mol.107.044636 PMID: 18326051; PubMed Central PMCID: PMC3437602.
42. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res. 2012; 18(18):4986-96. Epub 2012/07/25. [pii]. PMID: 22825581; PubMed Central PMCID: PMC3445706.
43. Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, et al. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther. 2009; 8(8):2211-20. doi: 10.1158/1535-7163.MCT-09-0327 PMID: 19638453; PubMed Central PMCID: PMC2768047.